College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
Curr Med Chem. 2021;28(13):2540-2564. doi: 10.2174/0929867327666200514082425.
Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of drug development and chemical synthesis.
肿瘤生长抑制可通过抑制血管生成来实现，这是近年来备受关注的领域。抑制血管生成的重要靶点包括血管内皮生长因子受体（VEGFR）及其同源酪氨酸激酶受体。基于 VEGFR-2 抑制的抗血管生成治疗是一种有效的临床治疗策略。本文从药物开发和化学合成两个方面综述了 VEGFR-2 抑制剂的研究进展。
